

# NYRx BLTG Program Update

---

## What Pharmacy Providers and Prescribers Need to Know

Effective **February 7, 2024**, the following changes will be made to the Dispense Brand Name Drug When Less Expensive Than the Generic Program:

- **Alphagan P® 0.1%, Forteo®, and Votrient®** will be **ADDED** to the program.
- **Flovent® HFA and Pennsaid® pump** will be **REMOVED** from the program.

**Note:** Pennsaid pump has been discontinued by the manufacturer. Diclofenac 2% topical solution will remain in non-preferred status on the [NYRx Preferred Drug List](#). Prescribers should transition their patients to an alternative preferred product or obtain a prior authorization for the diclofenac 2% solution.

In conformance with State Education Law, a pharmacist shall dispense a less expensive, therapeutically equivalent drug containing the same active ingredients, dosage form, and strength as the drug prescribed/ordered. This includes substituting the brand name drug when NYRx has determined it to be the less expensive alternative for the patient. Brand name drugs included in this program:

- Do not require "Dispense as Written" (DAW) or "Brand Medically Necessary" on the prescription.
- Have a generic copayment.
- Are paid at the Brand Name Drug reimbursement rate or usual and customary price, whichever is lower (SMAC/FUL are not applied).
- Do not require a new prescription if the drug is removed from this program.

## Important Billing Information

Pursuant to this program, prescription claims submitted to the Medicaid program **do not require** the submission of a DAW Product Selection Code of "1"; Pharmacies should **submit DAW code 9** (Substitution Allowed by Prescriber but Plan Requests Brand). Pharmacies will receive an NCPDP reject response of "22" which means missing/invalid DAW code if other DAW codes are submitted. The only exception to this is DAW code "1" and "Brand Medically Necessary" on the prescription.

For a complete list, see [NYRx BLTG Program Brand Name Drugs](#) on the next page.

## NYRx BLTG Drugs

NYRx BLTG Program Brand Name Drugs*		
Advair Diskus®	<b>Forteo®</b>	Restasis®
Advair HFA®	Glumetza®	Retin-A® cream
Alphagan P® 0.15%	Kazano®	Ritalin LA®
<b>Alphagan P® 0.1%</b>	Kitabis® Pak	Spiriva® HandiHaler®
Amitiza®	Kombiglyze® XR	Symbicort®
Apriso®	Lialda®	Tegretol® suspension
Azopt™	Nesina®	Tegretol® XR
Bethkis®	Nexavar®	Trileptal® suspension
Cellcept® suspension	NuvaRing®	Vascepa®
Combigan®	Onglyza®	Ventolin® HFA
Copaxone® 20mg SQ	Oseni®	<b>Votrient®</b>
Daytrana®	Pentasa®	Vyvanse® chewable tablet
Depakote® Sprinkle	Pradaxa®	Vyvanse® capsule
Dexilant®	Protonix® suspension	Xopenex HFA®
Dymista®	Pylera®	Zegerid® Rx
Epipen	Rapamune® solution	
Epipen, JR	Renvela® tablet, powder pack	

\* This list is subject to change. For the most recent updates, see the [Brand Less than Generic Program Updates](#).

\* Drugs in this program may be subject to prior authorization requirements of other pharmacy programs.

## Resources

- [NYRx Brand Less Than Generic Program](#)
- [NYRx Education & Outreach Website](#)
- [NYRx Preferred Drug List](#)

## Contact Information

The NYRx Education & Outreach Call Center is available by phone at 1-833-967-7310 from 8:00 AM to 5:00 PM ET, Monday through Friday, excluding holidays, or by email at [NYRxEO@magellanhealth.com](mailto:NYRxEO@magellanhealth.com).

The NYRx Education & Outreach team hosts virtual office hours every week for stakeholders to ask questions related to NYRx and care coordination. Office hours are also available by appointment. For more information, email [NYRxEO@magellanhealth.com](mailto:NYRxEO@magellanhealth.com) or visit the [NYRx Education & Outreach website](#).